$309.05-2.3%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed October 30, 2026
Company outlook: revenue of $225M to $250M for Fiscal year 2026 — down 11.4% on a year earlier ($268.1M)
Just reported
From Ligand Pharmaceuticals Inc.'s results release of October 29, 2026; its quarterly report has since been filed.
Actual
$78.7M
-32% y/y
+24% q/q
Guided
—
No guide given
Actual
-$1.43
Guided
—
No guide given
Actual
-$15.8M
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $78.7M | $115.5M | -31.80% |
| Profit | -$28.5M | $117.3M | -124.29% |
| Profit per share | -$1.43 | $5.68 | -125.18% |
| Free Cash Flow | -$27.7M | $13.1M | -312.11% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Ligand Pharmaceuticals Inc. has no earnings call transcript available.
“Ligand delivered another strong quarter, with royalty revenue growing 51% year-over-year, driven by contribution from the XOMA portfolio and continued commercial momentum across our key royalty assets, including Filspari,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Ligand is a leading royalty aggregator, partnering with biopharmaceutical companies to finance and advance late-stage clinical development programs. Ligand owns and manages one of the largest and most diversified portfolios of biopharmaceutical royalties in the industry, with economic interests in more than 200 development and commercial-stage assets. Ligand funds high-value programs in exchange for long-term economic interests, aligning capital with clinical and commercial success. Ligand’s royalty portfolio is designed to deliver consistent and predictable revenue streams across a broad range of therapeutic assets. Ligand also licenses its proprietary technologies, Captisol® and NITRICIL™, to support drug development and formulation across its global partner network.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Ligand Pharmaceuticals Inc.’s Item 2.02 8-K filed October 29, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Guided
—
No guide given
Full year 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.